Scarica l'app Stockscreener
3.93
2.08%
0.08
Pre-mercato:
3.95
0.02
+0.51%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
This Analyst Slashed CAPR Stock’s Target By 86% – But, Retail Bulls Say Setup Offers An Attractive Risk-Reward - Yahoo Finance
Capricor Therapeutics Faces Severe Stock Decline Amid FDA Concer - GuruFocus
CAPR Investor Alert: Capricor Therapeutics Investors Encouraged t - The National Law Review
Capricor Therapeutics: Downgrading To Sell As FDA Doubts Mount (NASDAQ:CAPR) - Seeking Alpha
Capricor Stock Tanks On FDA AdCom NotesWhat Investors Should Know (NASDAQ:CAPR) - Seeking Alpha
Replimune joins Capricor in post-briefing doc drop (REPL:NASDAQ) - Seeking Alpha
Alliance Global Partners Reiterates "Neutral" Rating for Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
B. Riley Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $10 From $63 - marketscreener.com
Roth Capital Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $7 From $38 - Moomoo
FDA panel raises doubts over Capricor’s deramiocel data ahead of DMD review - The Pharma Letter
CAPR|Capricor Therapeutics Inc|Price:7.000|Chg%:-12.700 - TradingKey
BREAKING: Capricor Therapeutics Investigated for Securities Fraud by Block & Leviton; Investors Should Contact the Firm to Learn More - Supply Chain Digital
Biotech Firms Face Critical FDA Review Events - Intellectia AI
Capricor’s Deramiocel Briefing Is a Masterclass in How Not to Define an Endpoint - The Clinical Trial Vanguard
Capricor Therapeutics Inc (CAPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Securities Investigation on Behalf of Capricor Investors - ACCESS Newswire
B.Riley downgrades Capricor stock on FDA briefing concerns By Investing.com - Investing.com UK
Capricor addresses FDA briefing materials ahead of advisory meeting - Investing.com India
CAPR Stock Eyes Worst Month In 9 Years On FDA Doubts — ‘Pharma Bro’ Shkreli Piles On, But Retail Turns More Bullish Than Ever - Stocktwits
Why Capricor Therapeutics (CAPR) Is Down 64.1% After FDA Flags Deramiocel Trial Concerns And Headquarters Bet - simplywall.st
Rosen Law Firm Encourages Capricor Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CAPR - Business Wire
Capricor Therapeutics (CAPR) Faces FDA Advisory Vote Amid Steep Stock Decline - GuruFocus
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug - STAT
CAPR Plunged About 64% After FDA Briefing Docs Hit. AdCom Is Wednesday. - Money Morning
FDA briefing casts doubt on Capricor’s deramiocel ahead of DMD AdCom - AllSci
Capricor Therapeutics (CAPR) Downgraded as FDA Briefing Raises A - GuruFocus
Capricor Therapeutics (CAPR) Shares Plunge Amid FDA Data Concerns, GF Score™ at 28 - GuruFocus
FDA staff report throws cold water on Capricor's DMD cell therapy bid - FirstWord Pharma
CAPR Investor Alert: Kehoe Law Firm, P.C. Investigates Capricor T - The National Law Review
UPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy - BioSpace
Capricor Therapeutics (NASDAQ:CAPR) Stock Rating Lowered by Roth Capital - MarketBeat
CAPR Stock On Track For Worst Day Ever — Analysts Divided On Deramiocel’s Approval Probability After FDA Documents Paint ‘Ugly Picture’ - Stocktwits
FDA staff flags data concerns about Capricor's therapy; shares plunge | Business Information & News | FE - Westlaw Today
Capricor Therapeutics stock falls after FDA briefing ahead of AdCom By Investing.com - Investing.com Australia
Capricor Therapeutics stock falls after FDA briefing ahead of AdCom - Investing.com
Investigation launched into Capricor Therapeuti... - Pluang
Market movers: Nvidia, Advanced Micro Devices, Capricor Therapeutics, SpaceX… - Proactive financial news
Capricor stock plunges 70% after FDA questions trial data for heart therapy. - Pluang
Capricor Therapeutics (CAPR) Prepares for FDA Advisory Committee Review on Deramiocel - GuruFocus
Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel - GlobeNewswire
Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel - GlobeNewswire Inc.
CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC - GlobeNewswire
Capricor Therapeutics (CAPR) Shares Plunge 67% After FDA Briefin - GuruFocus
H.C. Wainwright reiterates Capricor stock Buy rating at $60 target - Investing.com
Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Benzinga
Capricor Therapeutics (CAPR) Stock Plummets 63% Amid FDA Advisor - GuruFocus
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Capricor Therapeutics faces securities fraud pr... - Pluang
B.Riley downgrades Capricor stock on FDA briefing concerns - Investing.com
BREAKING: Capricor Therapeutics Investigated for Securities - GlobeNewswire
Capricor Therapeutics’ 67.7% collapse and the warning signs that preceded it - Investing.com
$Capricor Therapeutics (CAPR.US)$ waaa hit my first 🎯 - Moomoo
Capricor Therapeutics (NASDAQ:CAPR) Receives Neutral Rating from B. Riley Financial - MarketBeat
Adcom ‘cage match’ in store for Capricor? - BioWorld News
FDA scientists question Capricor data; Legend CEO steps down - BioPharma Dive
Capricor Therapeutics (NASDAQ:CAPR) shares tumble 67% after FDA raises concerns over Deramiocel data - TechStock²
Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document - Stocktwits
Oppenheimer reiterates Capricor stock rating ahead of FDA panel By Investing.com - Investing.com South Africa
Capricor addresses FDA briefing materials ahead of advisory meeting By Investing.com - Investing.com South Africa
FDA staff flags data concerns about Capricor's therapy; shares plunge - Reuters
Capricor Therapeutics stock tumbles after FDA briefing documents - Investing.com
Capricor updates ahead of FDA advisory meeting on Duchenne muscular dystrophy therapy Deramiocel. - Pluang
Capricor Provides Update on Deramiocel for DMD Ahead of FDA Meeting - Intellectia AI
Capricor Therapeutics Provides Update Ahead of FDA Advisory Committee Meeting on Deramiocel BLA for Duchenne Muscular Dystrophy - Quiver Quantitative
0.39%
1.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):